Technology
Technology
Although HERVs have been known targets for some time, they were undruggable due to the immunosuppressive nature of the expressed HERV proteins (mainly “envelope”).
Hervolution has overcome that by mutating the ISD domain within the HERV immunogen, as in our Lead Candidate IPT001.
We deliver our immunogen as cancer vaccines by using Adenoviral and RNA vectors.
Mechanism of Action
Conceptually, the immune system is evolutionary optimized to target viruses with antibodies and CD8+ T cells, supported by CD4+ T cells. Using Virus-Like-Vaccines encoding endogenous retroviruses, Hervolution unleashes the true potency of antiviral immunity against cancers.
Optimized immunogen to maximize immune responses and overcome immunosuppression
Optimized immunogen to maximize immune responses and overcome immunosuppression
Adenoviral and RNA-Vectored vaccines transduce Antigen Presenting Cells (APCS)
Optimized immunogen to maximize immune responses and overcome immunosuppression
Adenoviral and RNA-Vectored vaccines transduce Antigen Presenting Cells (APCS)
APCs activate B-cells (antibodies) and T-Cells (CD8+ and CD4+)
Optimized immunogen to maximize immune responses and overcome immunosuppression
Adenoviral and RNA-Vectored vaccines transduce Antigen Presenting Cells (APCS)
APCs activate B-cells (antibodies) and T-Cells (CD8+ and CD4+)
Antibodies, CD8+ and CD4+ against HERK, kill cancer cells
Optimized immunogen to maximize
immune responses and overcome
immunosuppression
1
Adenoviral and RNA-Vectored vaccines transduce Antigen Presenting Cells (APCS)
2
APCs activate B-cells (antibodies) and T-Cells (CD8+ and CD4+)
3
Antibodies, CD8+ and CD4+ against HERK, kill cancer cells
Pipeline
